We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Bordetella Test Delivers PCR-Accurate Results in 15 Minutes

By LabMedica International staff writers
Posted on 03 Dec 2025

Whooping cough remains difficult to diagnose early because its first symptoms resemble other respiratory infections, leading clinicians to treat empirically and often too late. With whooping cough cases rising due to disrupted vaccination schedules, waning immunity, and vaccine hesitancy, clinicians face increasing diagnostic pressure across all age groups. Now, a rapid point-of-care (POC) PCR test identifies and differentiates Bordetella infections within minutes, enabling targeted antibiotic therapy during the patient visit.

Roche Diagnostics’ (Basel, Switzerland) cobas liat Bordetella panel delivers results in just 15 minutes in primary care and emergency settings, allowing physicians to diagnose pertussis at POC and initiate immediate treatment to prevent severe complications and limit transmission. The test detects and differentiates three clinically important species: Bordetella pertussis, the cause of classic whooping cough; B. parapertussis, associated with a milder pertussis-like illness that may respond differently to treatment; and B. holmesii, an emerging pathogen known to complicate diagnosis.


Image: The cobas liat Bordetella panel has received FDA clearance along with CLIA waiver and CE Mark (Photo courtesy of Roche)
Image: The cobas liat Bordetella panel has received FDA clearance along with CLIA waiver and CE Mark (Photo courtesy of Roche)

The assay runs on the compact cobas liat platform and expands Roche’s existing menu of rapid PCR tests for SARS-CoV-2, Influenza A/B, RSV, and Group A Strep. By enabling multiple respiratory diagnoses directly during the consultation, the system reduces dependence on centralized laboratory testing and supports faster, more precise patient management. The cobas liat Bordetella panel has now received U.S. FDA 510(k) clearance, a CLIA waiver, and CE IVDR certification.

"Faster and more accurate clinical decisions are critical for reducing the risk of severe complications and ultimately stopping the transmission of Bordetella infections.” said Matt Sause, CEO of Roche Diagnostics. “This new test allows clinicians to quickly make a definitive and precise diagnosis to ensure patients get the right treatment earlier."


New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
New
Homocysteine Quality Control
Liquichek Homocysteine Control

Latest Molecular Diagnostics News

Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device
03 Dec 2025  |   Molecular Diagnostics

Pinprick Blood Test Could Detect Disease 10 Years Before Symptoms Appear
03 Dec 2025  |   Molecular Diagnostics

Refined C-Reactive Protein Cutoffs Help Assess Sepsis Risk in Preterm Babies
03 Dec 2025  |   Molecular Diagnostics



GLOBE SCIENTIFIC, LLC